全文获取类型
收费全文 | 79712篇 |
免费 | 2687篇 |
国内免费 | 117篇 |
专业分类
耳鼻咽喉 | 1120篇 |
儿科学 | 3597篇 |
妇产科学 | 2333篇 |
基础医学 | 8052篇 |
口腔科学 | 1469篇 |
临床医学 | 10098篇 |
内科学 | 12535篇 |
皮肤病学 | 1032篇 |
神经病学 | 7464篇 |
特种医学 | 3469篇 |
外科学 | 15576篇 |
综合类 | 178篇 |
一般理论 | 51篇 |
预防医学 | 5509篇 |
眼科学 | 1026篇 |
药学 | 4261篇 |
中国医学 | 46篇 |
肿瘤学 | 4700篇 |
出版年
2024年 | 9篇 |
2023年 | 2042篇 |
2022年 | 3693篇 |
2021年 | 3708篇 |
2020年 | 4288篇 |
2019年 | 2917篇 |
2018年 | 2213篇 |
2017年 | 2249篇 |
2016年 | 2276篇 |
2015年 | 2476篇 |
2014年 | 4475篇 |
2013年 | 3820篇 |
2012年 | 3905篇 |
2011年 | 3863篇 |
2010年 | 3158篇 |
2009年 | 3164篇 |
2008年 | 3225篇 |
2007年 | 3503篇 |
2006年 | 3286篇 |
2005年 | 2899篇 |
2004年 | 2552篇 |
2003年 | 2357篇 |
2002年 | 2043篇 |
2001年 | 1923篇 |
2000年 | 1680篇 |
1999年 | 1432篇 |
1998年 | 677篇 |
1997年 | 553篇 |
1996年 | 619篇 |
1995年 | 547篇 |
1994年 | 458篇 |
1993年 | 365篇 |
1992年 | 932篇 |
1991年 | 964篇 |
1990年 | 874篇 |
1989年 | 795篇 |
1988年 | 809篇 |
1987年 | 408篇 |
1986年 | 192篇 |
1985年 | 215篇 |
1984年 | 228篇 |
1983年 | 165篇 |
1982年 | 146篇 |
1981年 | 131篇 |
1980年 | 83篇 |
1979年 | 74篇 |
1978年 | 43篇 |
1977年 | 41篇 |
1976年 | 28篇 |
1975年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
《Current problems in cardiology》2022,47(12):101367
Percutaneous balloon mitral valvuloplasty (PBMV) is primarily performed for rheumatic mitral stenosis (MS). Therefore, limited data exist on PBMV in countries with a low incidence of rheumatic disease. Using the Nationwide Readmission Database, we examined trends in in-hospital mortality and 30-day readmission among patients who received PBMV for rheumatic and non-rheumatic MS. We also examined the change in 90-day hospitalization rate before vs after PBMV. Between 2016 and 2019, there were 1109 hospitalizations in which patients received PBMV for rheumatic (n = 955, 86.1%) vs non-rheumatic MS (n = 154, 13.9%). The all-cause in-hospital mortality for rheumatic and non-rheumatic MS did not change over time (0.9% → 2.0%, P = 0.94, and 5.9% → 9.5%, P = 0.09 respectively). Similarly, the 30-day readmission for patients with rheumatic and non-rheumatic MS did not change over time (12.4% → 9.9%, P = 0.26, and 4.4% → 10.5%, P = 0.30, respectively). The 90-day all-cause hospitalization rate remained the same before vs after PBMV for rheumatic and non-rheumatic MS (25.5% → 21.8%; P = 0.14, and 24.0% → 33.7%; P = 0.19, respectively). Although no statistically significant change was noted over time for trends in in-hospital mortality, 30-day readmission, or even in the change in 90-day all-cause hospitalizations before and after PBMV for both types of MS, among those with non-rheumatic MS, there was a signal of an increase in the in-hospital mortality, and 30-day readmission, even more, there was 29% relative increase in 90-day hospitalizations after PBMV. Future studies are needed to examine the role of PBMV in patients with non-rheumatic MS. 相似文献
82.
83.
84.
85.
86.
ObjectiveThis study aimed to determine the contribution of EFHC1 variants to the phenotypic variability of juvenile myoclonic epilepsy (JME) and to evaluate their diagnostic value regarding previously identified clinical long-term seizure outcome predictors in a consecutive cohort of patients with JME.MethodsThirty-eight probands and three family members affected with JME were studied at a tertiary epilepsy center with a review of their medical records and a subsequent face-to-face interview. All coding EFHC1 exons and adjacent exon/intron boundaries were directly sequenced.ResultsThe previously reported EFHC1 mutation F229L was found in two cases who presented with early generalized tonic–clonic seizure (GTCS) onset and appeared to be associated with milder subtypes of JME. Variant R294H was identified in two further probands who had a subtype of JME developing from childhood absence epilepsy. However, segregation of the phenotype with this variant could not be confirmed in one family.ConclusionsOur findings corroborate the heterogeneity of JME as an electroclinical epilepsy syndrome and provide evidence that genetic factors may influence and help predict the long-term seizure outcome in patients with JME. 相似文献
87.
Sundaram Kavin Piuzzi Nicolas S. Patterson Brendan M. Stearns Kim L. Krebs Viktor E. Mont Michael A. 《European journal of orthopaedic surgery & traumatology : orthopedie traumatologie》2020,30(3):447-453
European Journal of Orthopaedic Surgery & Traumatology - The goals of this study were to compare patient satisfaction and wound-related complications in patients receiving 2-octyl cyanoacrylate... 相似文献
88.
89.
90.
《Genetics in medicine》2020,22(11):1794-1802
PurposeNeurofibromatosis type 1 (NF1) is associated with tumor predisposition and nonmalignant health conditions. Whether survivors of childhood cancer with NF1 are at increased risk for poor long-term health outcomes is unknown.MethodsOne hundred forty-seven 5+ year survivors of childhood glioma with NF1 from the Childhood Cancer Survivor Study were compared with 2629 non-NF1 glioma survivors and 5051 siblings for late mortality, chronic health conditions, and psychosocial, neurocognitive, and socioeconomic outcomes.ResultsSurvivors with NF1 (age at diagnosis: 6.8 ± 4.8 years) had greater cumulative incidence of late mortality 30 years after diagnosis (46.3% [95% confidence interval: 23.9–62.2%]) compared with non-NF1 survivors (18.0% [16.1–20.0%]) and siblings (0.9% [0.6–1.2%]), largely due to subsequent neoplasms. Compared with survivors without NF1, those with NF1 had more severe/life-threatening chronic conditions at cohort entry (46.3% [38.1–54.4%] vs. 30.8% [29.1–32.6%]), but similar rates of new conditions during follow-up (rate ratio: 1.26 [0.90–1.77]). Survivors with NF1 were more likely to report psychosocial impairments, neurocognitive deficits, and socioeconomic difficulties compared with survivors without NF1.ConclusionsLate mortality among glioma survivors with NF1 is twice that of other survivors, due largely to subsequent malignancies. Screening, prevention, and early intervention for chronic health conditions and psychosocial and neurocognitive deficits may reduce long-term morbidity in this vulnerable population. 相似文献